FOR RESEARCH PURPOSES ONLY: This product is strictly intended for research purposes only. All information provided on this website is for educational use. It is not intended for human or animal use and must not be introduced into the body. Only qualified, licensed professionals should handle this material. This product is not classified as a drug, food, or cosmetic.
What is Human Menopausal Gonadotropin (HMG)?
Human Menopausal Gonadotropin (HMG), also referred to as menotropin, is a gonadotropin preparation containing both Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), traditionally extracted from the urine of postmenopausal donors in an approximate 1:1 ratio. Unlike HCG, which only mimics LH activity, HMG delivers a dual-action signal that engages both the Leydig cells (driving testosterone synthesis) and the Sertoli cells (driving spermatogenesis). In male research models, HMG is studied for its ability to restore complete testicular function, particularly when LH-mimetic compounds alone (such as HCG) fail to produce measurable sperm output. This makes HMG a critical compound in advanced fertility recovery and HPG axis restoration protocols following long-term suppression by exogenous hormones.
HMG Benefits & Research:
- Dual FSH + LH Activity: Provides both follicle-stimulating and luteinizing hormone signaling, engaging Sertoli and Leydig cells simultaneously in male research subjects.
- Spermatogenesis Restoration: The FSH component directly supports Sertoli cell function, which regulates the structural and metabolic environment required for sperm maturation in suppressed test subjects.
- Advanced Fertility Recovery: Frequently studied as an add-on compound when HCG monotherapy fails to produce measurable sperm output, addressing FSH deficiency that HCG cannot resolve.
- Endogenous Testosterone Support: The LH component continues to stimulate testicular testosterone production, complementing the FSH-driven spermatogenic effect.
- Post-Suppression Rebound: Investigated in models recovering from prolonged anabolic-induced shutdown, where both gonadotropin signals are needed to fully reactivate the hypothalamic-pituitary-gonadal (HPG) axis.
- Synergistic Stack Compound: Often researched alongside HCG and SERMs (such as Clomid or Nolvadex) to build a layered recovery protocol targeting every level of the HPG axis.
- Protocol Versatility: Studied across a range of dosing frequencies (commonly 75–150 IU, two to three times weekly in research literature) depending on the desired endpoint, whether full fertility recovery or maintenance during suppressive regimens.
